Recall: Quinapril-Hctz
Nov. 2022Pharmacy Updates
Aurobindo Pharma USA Inc. has recalled two lots of quinapril and hydrochlorothiazide tablets due to detection of a nitrosamine (N-nitrosoquinapril) impurity in amounts above the Acceptable Daily Intake level. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Read the full text of the Quinapril-Hctz recall.
Recent Announcements
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices